Osimertinib (Tagrisso) has a strong foothold as first-line therapy for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), but resistance to the third-generation EGFR tyrosine ...

CHICAGO — Adjuvant osimertinib conferred a significant OS benefit vs. placebo among patients with resected, EGFR-mutant, stage IB to IIIA non-small cell lung cancer, according to results of the ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 ...

Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based ...

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

First-line osimertinib improved OS compared with standard-of-care epidermal growth factor receptor tyrosine kinase inhibitors among patients with previously untreated advanced EGFR-mutated non ...

NSCLC: Osimertinib on Fast Track to Beat EGFR TKI Resistance – Third-generation agent may finally surpass T970M mutations by Shalmali Pal , Contributing Editor, MedPage Today February 10, 2017 ...

TAGRISSO ® (osimertinib) Important Safety Information There are no contraindications for TAGRISSO Interstitial Lung Disease (ILD)/Pneumonitis occurred in 3.5% and was fatal in 0.6% of 833 ...

Osimertinib, sold under the brand name Tagrisso, is available to patients with Stage 1B-3A lung cancer who have a certain genetic mutation and have had surgery to remove cancerous tumors.

Osimertinib has been approved since February 2016 for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small ...

Osimertinib (Tagrisso, AstraZeneca) cemented its role as front-line treatment of epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) in last year's FLAURA trial.

Osimertinib is one of the newest in a class of tyrosine kinase inhibitors (TKIs) that target the epidermal growth factor receptor (EGFR) in non–small cell lung cancer (NSCLC).